Welcome to our dedicated page for Alkermes Plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes Plc stock.
Alkermes plc (Nasdaq: ALKS) is a global biopharmaceutical company focused on neuroscience, and its news flow reflects both commercial execution and clinical development in this area. Company announcements emphasize proprietary products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, alongside a growing pipeline targeting neurological disorders such as narcolepsy and idiopathic hypersomnia.
Recent news has highlighted alixorexton, Alkermes investigational oral, selective orexin 2 receptor agonist. The company has reported positive phase 2 data from the Vibrance-1 study in narcolepsy type 1 and the Vibrance-2 study in narcolepsy type 2, and has announced that alixorexton is being evaluated in the Vibrance-3 study in idiopathic hypersomnia. In a separate update, Alkermes disclosed that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to alixorexton for narcolepsy type 1, based on phase 1 and phase 2 data.
Investors following ALKS news will also see regular earnings releases, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, and provides updates to its financial expectations. These releases describe trends in proprietary product sales, including VIVITROL, ARISTADA and LYBALVI, and manufacturing and royalty revenues related to VUMERITY and certain long-acting antipsychotic products.
Another key theme in Alkermes news is corporate transactions and financing. The company has announced a transaction agreement, and later an amendment, to acquire Avadel Pharmaceuticals plc, adding LUMRYZ, an FDA-approved once-at-bedtime oxybate for narcolepsy, to its commercial portfolio if the transaction is completed. Related filings describe an amended and restated bridge term loan credit agreement designed to support financing of the proposed acquisition.
Visitors to the ALKS news page can expect updates on clinical trial milestones, regulatory designations, quarterly financial performance, investor conference participation and material corporate agreements. This mix of scientific, financial and strategic information provides context for understanding Alkermes evolving position in neuroscience and sleep medicine.
Alkermes (Nasdaq: ALKS) initiated the Phase 3 Brilliance Studies of alixorexton, an oral selective orexin 2 receptor agonist, in adults with narcolepsy type 1 and type 2 on April 1, 2026. The program comprises three 12-week, randomized, double-blind, placebo-controlled studies testing once-daily and split-dose regimens.
Primary endpoints measure wakefulness by mean sleep latency on the MWT; secondary endpoints include ESS, weekly cataplexy rate, patient-reported outcomes, safety, and long-term open-label follow-up eligibility.
Alkermes (Nasdaq: ALKS) launched the inaugural Alkermes Pathways APN Research Awards™, a competitive grant program open March 16, 2026 through June 1, 2026. The program offers individual research grants up to $10,000 to licensed psychiatric-mental health nurse practitioners studying schizophrenia or bipolar I disorder.
Applicants must work in clinical, academic, or community health settings and hold a doctoral degree or have a doctoral co-investigator; awards will be reviewed by an independent committee.
Alkermes (Nasdaq: ALKS) will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 8:30 a.m. ET (12:30 p.m. GMT). The live webcast will be available under the Investors tab at www.alkermes.com and will be archived for 14 days for later viewing.
The company description notes a neuroscience-focused pipeline with late-stage narcolepsy and idiopathic hypersomnia candidates and early-stage orexin 2 receptor agonists for neurological disorders.
Alkermes (Nasdaq: ALKS) reported fourth-quarter and full-year 2025 financial results and issued 2026 financial expectations on Feb 25, 2026. The company will host a conference call and webcast at 8:00 a.m. EST the same day to discuss results and outlook.
The release highlights Alkermes' commercial neuroscience portfolio and ongoing clinical programs in narcolepsy, idiopathic hypersomnia and orexin 2 receptor agonists for other neurological disorders.
Alkermes (Nasdaq: ALKS) announced a planned CEO succession: Richard Pops will retire as CEO effective July 31, 2026, and Blair Jackson will become CEO effective Aug. 1, 2026, while Pops will remain as Board chairman and advisor.
The company cites ~$1.5 billion annual revenue, the recent acquisition of Avadel and an advancing orexin agonist pipeline including an FDA Breakthrough Therapy designation for alixorexton for narcolepsy type 1.
Alkermes (Nasdaq: ALKS) said management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT).
The live webcast will be available under the Investors tab at www.alkermes.com and will be archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience with marketed products for addiction, schizophrenia, bipolar I disorder and narcolepsy and a pipeline including late-stage narcolepsy and idiopathic hypersomnia programs.
Alkermes (Nasdaq: ALKS) completed its acquisition of Avadel on Feb. 12, 2026, adding FDA-approved LUMRYZ® and a commercial sleep-medicine organization.
The all-cash deal used ~$775 million in cash and $1.525 billion of term loans, is expected to be accretive in 2026, and adds a phase 1 candidate, valiloxybate.
Alkermes (Nasdaq: ALKS) will report fourth quarter and year-end 2025 financial results on Feb. 25, 2026 and host a conference call and webcast at 8:00 a.m. ET (1:00 p.m. GMT).
Management will review 2025 results, discuss 2026 financial expectations and provide a corporate update. Webcast slides and a replay will be available on the company website.
Alkermes (Nasdaq: ALKS) announced that the U.S. FDA granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1) on January 6, 2026.
The designation is based on phase 1 and phase 2 data, including positive results from Vibrance-1 (n=92), where alixorexton met the primary endpoint with statistically significant, dose-dependent improvements on the Maintenance of Wakefulness Test (MWT) and was generally well tolerated. Alkermes plans to initiate a global phase 3 program in Q1 2026.
Alkermes (Nasdaq: ALKS) said CEO Richard Pops will deliver a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST / 6:30 p.m. GMT).
The presentation will be available live via webcast under the Investors tab at www.alkermes.com and will be archived for 14 days.
Alkermes is a mid-cap biopharmaceutical company focused on neuroscience, with marketed products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a clinical pipeline including programs in narcolepsy and idiopathic hypersomnia.